The country’s Health Ministry announced on Thursday that Kovaxin, India’s locally developed vaccine, has been licensed for emergency use similar to the Oxford-AstraZeneca vaccine.
Kovaxin has been part of the country’s vaccine rollout since 16 January. However, it was rolled out under a “clinical trial mode”, which meant that patients had to sign an informed consent form and later required monitoring.
More than 1.9 million doses of kovaxine have already been administered.
Now, Phase 3 trials have shown an efficacy rate of 81%, and the vaccine has been granted approval under the “regular” emergency authority.
VK Paul of Neeti Ayog, an Indian government-led think tank, said, “It has taken the authority for kovaxin to the next level, at the same level as operating another great vaccine covishield.”
Mounting case: India fights a nail fight in transition as approval. The country recorded 23,139 new cases on Friday – the 24-hour increase for the second consecutive day since Christmas Day.
According to the Indian Ministry of Health, there have been a total of 11,308,846 cases and 158,306 related deaths in the country.
About 60% of new cases are in the western state of Maharashtra, which is a “worrying” trend, it said Dr. Director General of Indian Council of Medical Research. Balaram Bhargava said.
“This is related to testing, tracking and tracing, as well as Kovid-inappropriate behavior and low numbers of large gatherings,” Bhargava said in a press briefing on Thursday.